Clinical Trials Logo

Ocular Hypertension clinical trials

View clinical trials related to Ocular Hypertension.

Filter by:

NCT ID: NCT04957329 Recruiting - Glaucoma Clinical Trials

Effect of Benzalkonium Chloride Preserved and Preservative-free Latanoprost Eye Drops on Conjunctival Goblet Cells

Start date: September 1, 2021
Phase: Phase 4
Study type: Interventional

a randomized, investigator-blind, interventinal study will compare the effect of benzalkonium-chloride (BAK) preserved and preservative-free (PF) eye drops on conjunctival goblet cells.

NCT ID: NCT04947124 Completed - Glaucoma Clinical Trials

A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101

Start date: October 19, 2021
Phase: Phase 2
Study type: Interventional

Safety and tolerability study of 2 concentrations of QLS-101 for adult subjects with Sturge Weber Syndrome (SWS)-related glaucoma due to elevated episcleral venous pressure (EVP).

NCT ID: NCT04944290 Completed - Ocular Hypertension Clinical Trials

To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes

Start date: May 28, 2021
Phase: Phase 3
Study type: Interventional

To compare the efficacy and safety of Perrigo's product to an FDA approved product in the treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes.

NCT ID: NCT04931316 Recruiting - Clinical trials for Unrecognized Condition

Incidence and Management of Ocular Hypertension Following Deep Anterior Lamellar Keratoplasty

Dalk
Start date: March 15, 2021
Phase:
Study type: Observational

This is a retrospective case series study that included patients who performed deep anterior lamellar keratoplasty and presented with elevated intraocular pressure during follow up.

NCT ID: NCT04911387 Completed - Glaucoma Clinical Trials

iCare® Home vs Goldmann Applanation Tonometry

Start date: April 1, 2020
Phase:
Study type: Observational

Self-tonometry with iCare Home is regularly performed at Sankt Erik's Eye Hospital since a few years back. The purpose of this study was to show that the eye pressure measurements made with iCare® Home by patients / relatives do not vary more than those made with the standard method, Goldman applanation tonometry (GAT), by different healthcare professionals. This will hopefully confirm the usefulness of self-tonometry.

NCT ID: NCT04910100 Completed - Ocular Hypertension Clinical Trials

Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension

Start date: April 15, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety (in the eye and throughout the body) and effectiveness of nebivolol (0.5 and 1 percent) and timolol (0.5 percent) eye drop suspensions. These eye drops will be compared to timolol 0.5 percent eye drop solution in participants with open angle glaucoma (the most common type of glaucoma) or high eye pressure (ocular hypertension).

NCT ID: NCT04898387 Completed - Clinical trials for Ocular Hypertension Glaucoma

Efficacy and Safety Assessment of T4030 Eye Drops Versus Ganfort® UD in Ocular Hypertensive or Glaucomatous Patients.

Start date: March 26, 2021
Phase: Phase 3
Study type: Interventional

To demonstrate the non-inferiority of T4030 unpreserved eye drops compared to Ganfort® UD in terms of efficacy.

NCT ID: NCT04891588 Recruiting - Ocular Hypertension Clinical Trials

Switching From the Preserved to the Preservative - Free Latanoprost - Timolol FC in Glaucoma Patients With OSD

Start date: March 8, 2021
Phase: N/A
Study type: Interventional

Glaucoma is a group of chronic eye diseases that are characterized by a progressive optic nerve damage and consequent visual loss. In most cases, it is associated with elevated intraocular pressure. If glaucoma left untreated, complete blindness can occur. Prostaglandin analog- timolol FCs are common glaucoma therapy because these drugs have been shown to effectively lower intraocular pressure (IOP). It is also known that chronic use of preservatives in the drops leads to ocular surface disease (OSD) which can lead to low tolerability of prescribed drops and gaps in the dosing regimen. The purpose of this study is to investigate whether drug preservative elimination results in reduction of OSD symptoms and signs as well as improvement of latanoprost-timolol FC local tolerability in the treatment of glaucoma and ocular hypertension. In this trial, on each visit (V1, V2 and V3) following tests will be used: Snellen visual acuity, IOP measurement by Goldman applanation tonometry, OSD signs assessment on the slit lamp (corneal and conjunctival fluorescein surface staining, conjunctival hyperemia and tear film stability assessment using Tear Break- up Time test - TBUT). Visual Analog Scale (VAS) will be used for a subjective assessment of drug tolerability. The association of quality of life and dry eye symptoms in participants will be measured by the Ocular Surface Disease Index (OSDI) questionnaire.

NCT ID: NCT04888156 Completed - Glaucoma Clinical Trials

Impact of Self-tonometry on Glaucoma Treatment Decision.

Start date: May 10, 2021
Phase:
Study type: Observational

Self-tonometry with iCare Home is performed by one hundred patients annually at Sankt Erik's Eye Hospital. The investigators want to evaluate the impact that self-tonometry results have on the clinician's choice of glaucoma treatment. The investigators also want to evaluate how often pressure peaks occur outside the clinic's opening hours.

NCT ID: NCT04863365 Not yet recruiting - Ocular Hypertension Clinical Trials

A Study of Efficacy and Safety of PHP-201 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Start date: November 2021
Phase: Phase 3
Study type: Interventional

This is a phase 3 study to confirm the efficacy in reduction of intraocular pressure and safety of PHP-201 ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension.